{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:38:45Z","timestamp":1791841125874,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,15]]},"DOI":"10.1093\/cid\/ciu592","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T12:21:34Z","timestamp":1414498894000},"page":"S360-S364","source":"Crossref","is-referenced-by-count":62,"title":["Immunosuppression Associated With Novel Chemotherapy Agents and Monoclonal Antibodies"],"prefix":"10.1093","volume":"59","author":[{"given":"Vicki A.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,15]]},"reference":[{"key":"key\n\t\t\t\t20171013234935_CIU592C1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171013234935_CIU592C2","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C3","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/10428190310001624152","article-title":"Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory\/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)\u2014Polish multicentre study","volume":"45","author":"Kowal","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171013234935_CIU592C6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C7","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C8","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C9","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C11","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013234935_CIU592C13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20171013234935_CIU592C14","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171013234935_CIU592C15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428190903150839","article-title":"Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901","volume":"50","author":"Byrd","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171013234935_CIU592C16","doi-asserted-by":"crossref","first-page":"233a","DOI":"10.1182\/blood.V110.11.756.756","article-title":"Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: a comparative analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)","volume":"110","author":"Morrison","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C17","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CLM.2006.n.049","article-title":"Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"7","author":"O'Brien","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"key\n\t\t\t\t20171013234935_CIU592C19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Practice Res Clin Haematol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C20","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013234935_CIU592C21","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C22","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3109\/10428194.2013.772294","article-title":"Herpes zoster complicating bortezomib therapy of relapsed\/refractory indolent B-cell and mantle cell lymphoma: An analysis of two phase II trials","volume":"54","author":"Sohl","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171013234935_CIU592C23","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.3748\/wjg.v17.i34.3881","article-title":"Current trends in management of hepatitis B virus reactivation in the biologic therapy era","volume":"17","author":"Mastroianni","year":"2011","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C24","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00520-012-1576-7","article-title":"Hepatitis B virus management to prevent reactivation after chemotherapy: a review","volume":"20","author":"Hwang","year":"2012","journal-title":"Support Care Cancer"},{"key":"key\n\t\t\t\t20171013234935_CIU592C25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaut.2011.08.002","article-title":"Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases","volume":"37","author":"Borchers","year":"2011","journal-title":"J Autoimmunity"},{"key":"key\n\t\t\t\t20171013234935_CIU592C27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1469-0691.2011.03653.x","article-title":"Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies","volume":"17","author":"Tavazzi","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171013234935_CIU592C28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.berh.2011.06.001","article-title":"Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-\u03b1) era","volume":"25","author":"Nacci","year":"2011","journal-title":"Best Practice Res Clin Immunol"},{"key":"key\n\t\t\t\t20171013234935_CIU592C29","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/acr.21805","article-title":"Use of a disease risk score to compare serious infections associated with anti\u2013tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20171013234935_CIU592C30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171013234935_CIU592C31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-\u03b1 treatment","volume":"60","author":"Ormerod","year":"2005","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20171013234935_CIU592C32","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013234935_CIU592C33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor \u03b1 blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20171013234935_CIU592C34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-\u03b1 agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"J Amer Med Assoc"},{"key":"key\n\t\t\t\t20171013234935_CIU592C35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides\u2014a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171013234935_CIU592C36","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"J Amer Med Assoc"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/59\/suppl_5\/S360\/20911971\/ciu592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T01:48:28Z","timestamp":1598406508000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/59\/suppl_5\/S360\/280808\/Immunosuppression-Associated-With-Novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,15]]},"references-count":36,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2014,11,15]]},"published-print":{"date-parts":[[2014,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu592","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,11,15]]},"published":{"date-parts":[[2014,11,15]]}}}